Ruth Ben-Yakar

Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.

Thrombotech Ltd. is an Israel-based biotechnological company that is based on years of cutting-edge thrombotic research at the Hadassah Medical Center in Jerusalem. Thrombotech developed a peptide called THR-18, which allows the existing thrombolytic stroke medication to easily dissolve blood clots, extending its short therapeutic time window and diminishing life-threatening side effects. The company was founded in 2000 and is headquartered in Rehovot, Israel.

Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.

Yeda Research & Development Co. Ltd. engages in development of natural science and services. It covers broad of spectrum including: biotechnology, pharmaceuticals and diagnostics, bioinformatics, proteomics, biomatics and system biology, medical devices, renewable energy, bio fuels, clean technology and environmental sciences, agricultural and plants genetics, chemistry and nanotechnology, physics and electro-optics, mathematics and computer science. The company is headquartered in Rehovot, Israel.

BioSight Ltd. is a clinical stage biotechnology company engaging in the development of therapeutics for hematological malignancies and disorders. The company was founded by Stela Gengrinovitchan and Mark Gengrinovitch on November 10, 1999 and is headquartered in Lod, Isreal.